$121.12
0[0.00%]
At close: May 17
$121.12
0[0.00%]
PreMarket: 4:00PM EDT
Ascendis Pharma
(NASDAQ:ASND)Ascendis Pharma Stock (NASDAQ:ASND), Analyst Ratings, Price Targets, Predictions
Ascendis Pharma A/S has a consensus price target of $157.56, established from looking at the 91 latest analyst ratings. The last 3 analyst ratings were released from Morgan Stanley, Cantor Fitzgerald, and Wells Fargo on May 16, 2024, May 15, 2024, and May 3, 2024. With an average price target of $191.67 between Morgan Stanley, Cantor Fitzgerald, and Wells Fargo, there's an implied 58.25% upside for Ascendis Pharma A/S from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
Cantor Fitzgerald
Wells Fargo
JP Morgan
Citigroup
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Ascendis Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/16/2024 | Buy Now | 15.59% | Morgan Stanley | Vikram Purohit | $116 → $140 | Maintains | Equal-Weight | Get Alert |
| 05/15/2024 | Buy Now | 42.83% | Cantor Fitzgerald | Li Watsek | → $173 | Reiterates | Overweight → Overweight | Get Alert |
| 05/03/2024 | Buy Now | 116.31% | Wells Fargo | Derek Archila | $260 → $262 | Maintains | Overweight | Get Alert |
| 05/03/2024 | Buy Now | 40.36% | JP Morgan | Jessica Fye | $167 → $170 | Maintains | Overweight | Get Alert |
| 05/03/2024 | Buy Now | 42.83% | Cantor Fitzgerald | Li Watsek | → $173 | Reiterates | Overweight → Overweight | Get Alert |
| 04/22/2024 | Buy Now | -4.23% | Morgan Stanley | Vikram Purohit | $116 → $116 | Maintains | Equal-Weight | Get Alert |
| 04/18/2024 | Buy Now | 42.83% | Cantor Fitzgerald | Li Watsek | → $173 | Reiterates | Overweight → Overweight | Get Alert |
| 04/02/2024 | Buy Now | 37.88% | JP Morgan | Jessica Fye | $165 → $167 | Maintains | Overweight | Get Alert |
| 04/01/2024 | Buy Now | 42.83% | Cantor Fitzgerald | Li Watsek | → $173 | Reiterates | Overweight → Overweight | Get Alert |
| 03/15/2024 | Buy Now | 114.66% | Wells Fargo | Derek Archila | $196 → $260 | Maintains | Overweight | Get Alert |
| 02/08/2024 | Buy Now | 50.26% | Citigroup | David Lebowitz | $146 → $182 | Maintains | Buy | Get Alert |
| 02/08/2024 | Buy Now | 85.77% | Wedbush | Andreas Argyrides | $207 → $225 | Maintains | Outperform | Get Alert |
| 02/06/2024 | Buy Now | 42.83% | Cantor Fitzgerald | Li Watsek | $152 → $173 | Maintains | Overweight | Get Alert |
| 12/20/2023 | Buy Now | 25.5% | Cantor Fitzgerald | Li Watsek | → $152 | Reiterates | Overweight → Overweight | Get Alert |
| 12/20/2023 | Buy Now | 66.78% | Wedbush | Andreas Argyrides | $200 → $202 | Maintains | Outperform | Get Alert |
| 12/20/2023 | Buy Now | 23.84% | Jefferies | Kelly Shi | → $150 | Initiates | → Buy | Get Alert |
| 12/19/2023 | Buy Now | 23.02% | Wells Fargo | Derek Archila | $137 → $149 | Maintains | Overweight | Get Alert |
| 11/09/2023 | Buy Now | -4.23% | Morgan Stanley | Vikram Purohit | $113 → $116 | Maintains | Equal-Weight | Get Alert |
| 11/08/2023 | Buy Now | 58.52% | Wedbush | Andreas Argyrides | → $192 | Reiterates | Outperform → Outperform | Get Alert |
| 09/15/2023 | Buy Now | 25.5% | Cantor Fitzgerald | Li Watsek | → $152 | Reiterates | Overweight → Overweight | Get Alert |
| 09/07/2023 | Buy Now | 25.5% | Cantor Fitzgerald | Li Watsek | → $152 | Reiterates | Overweight → Overweight | Get Alert |
| 09/06/2023 | Buy Now | 10.63% | Wells Fargo | Derek Archila | $139 → $134 | Maintains | Overweight | Get Alert |
| 09/06/2023 | Buy Now | 58.52% | Wedbush | Andreas Argyrides | $187 → $192 | Maintains | Outperform | Get Alert |
| 09/06/2023 | Buy Now | -6.7% | Morgan Stanley | Vikram Purohit | $109 → $113 | Maintains | Equal-Weight | Get Alert |
| 08/07/2023 | Buy Now | -10.01% | Morgan Stanley | Vikram Purohit | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/01/2023 | Buy Now | -10.01% | Morgan Stanley | Vikram Purohit | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/31/2023 | Buy Now | -10.01% | Morgan Stanley | Vikram Purohit | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/24/2023 | Buy Now | -10.01% | Morgan Stanley | Vikram Purohit | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/17/2023 | Buy Now | -10.01% | Morgan Stanley | Vikram Purohit | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/26/2023 | Buy Now | -10.01% | Morgan Stanley | Vikram Purohit | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
FAQ
What is the target price for Ascendis Pharma (ASND)?
The latest price target for Ascendis Pharma (NASDAQ: ASND) was reported by Morgan Stanley on May 16, 2024. The analyst firm set a price target for $140.00 expecting ASND to rise to within 12 months (a possible 15.59% upside). 36 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ascendis Pharma (ASND)?
The latest analyst rating for Ascendis Pharma (NASDAQ: ASND) was provided by Morgan Stanley, and Ascendis Pharma maintained their equal-weight rating.
When was the last upgrade for Ascendis Pharma (ASND)?
The last upgrade for Ascendis Pharma A/S happened on March 15, 2022 when B of A Securities raised their price target to $161. B of A Securities previously had a neutral for Ascendis Pharma A/S.
When was the last downgrade for Ascendis Pharma (ASND)?
The last downgrade for Ascendis Pharma A/S happened on April 5, 2023 when Oppenheimer changed their price target from N/A to N/A for Ascendis Pharma A/S.
When is the next analyst rating going to be posted or updated for Ascendis Pharma (ASND)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ascendis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ascendis Pharma was filed on May 16, 2024 so you should expect the next rating to be made available sometime around May 16, 2025.
Is the Analyst Rating Ascendis Pharma (ASND) correct?
While ratings are subjective and will change, the latest Ascendis Pharma (ASND) rating was a maintained with a price target of $116.00 to $140.00. The current price Ascendis Pharma (ASND) is trading at is $121.12, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.